title: Differential sensitivity of human colonic adenoma and carcinoma cells to transforming growth factor beta (TGF-beta): conversion of an adenoma cell line to a tumorigenic phenotype is accompanied by a reduced response to the inhibitory effects of TGF-beta.
abstract: The growth of three non-tumorigenic human colonic adenoma cell lines, designated AA/C1, RG/C2 and RR/C1, was inhibited by low concentrations of transforming growth factor beta (TGF-beta) (0.05-0.5 ng ml-1). However, the growth of five human colon cancer cell lines under identical conditions was resistant to high concentrations of TGF-beta (2-10 ng ml-1). This is the first report of well-characterized premalignant human colonic cells showing sensitivity to TGF-beta. The TGF-beta-sensitive adenoma cell line AA/C1 was derived from a relatively large adenoma with a K-ras gene mutation and represents a relatively late-stage adenoma, indicating that loss of response to TGF-beta occurs at a relatively late stage in colorectal carcinogenesis and that the presence of a ras gene mutation does not necessarily confer resistance to TGF-beta. Of further interest, the RG/CZ cell line has a p53 mutation showing that p53 mutations do not necessarily lead to TGF-B insensitivity. Furthermore, in this paper we show that the conversion of the AA/C1 adenoma cell line to a tumorigenic phenotype [Williams et al., (1990) Cancer Res., 50, 4724] is accompanied by a reduced response to the growth-inhibitory effects of TGF-beta up to 10 ng ml-1. Reduced responsiveness to the inhibitory effects of TGF-beta may be an important event in the loss of growth control in colorectal carcinogenesis.
authors.affiliation: Department of Pathology and Microbiology, University of Bristol, School of Medical Sciences, UK.
authors.forename: A M
authors.initials: AM
authors.lastname: Manning
authors.forename: A C
authors.initials: AC
authors.lastname: Williams
authors.forename: S M
authors.initials: SM
authors.lastname: Game
authors.forename: C
authors.initials: C
authors.lastname: Paraskeva
mesh_terms: D000236:Adenoma / Q000235:genetics / Q000473:pathology* / Q000503:physiopathology; D002277:Carcinoma / Q000235:genetics / Q000473:pathology* / Q000503:physiopathology; D002461:Cell Line, Transformed; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000473:pathology*; D015179:Colorectal Neoplasms / Q000235:genetics / Q000473:pathology* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance / Q000235:genetics / Q000502:physiology; D011905:Genes, ras / Q000235:genetics / Q000502:physiology; D006801:Humans; D009154:Mutation / Q000235:genetics; D010641:Phenotype; D011230:Precancerous Conditions / Q000473:pathology; D016212:Transforming Growth Factor beta / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000473:pathology
chemical_list: D016212:Transforming Growth Factor beta